

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**  
**諾輝健康**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 6606)**

## **VOLUNTARY ANNOUNCEMENT**

### **LISTING OF THREE PRODUCTS UNDER HONG KONG MEDICAL DEVICE ADMINISTRATIVE CONTROL SYSTEM**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**” or “**We**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business update of the Group.

The Company is pleased to announce that, recently, three products of the Company, namely (i) ColoClear, a proprietary non-invasive stool-based FIT-DNA screening test for colorectal cancer, (ii) Pupu Tube, a proprietary non-invasive stool-based FIT screening product to detect hemoglobin biomarkers associated with colorectal cancer, and (iii) UU Tube, a stool-based self-conducted screening product for H. pylori, have been successfully listed with the Department of Health (the “**Department of Health**”) of the Government (the “**Hong Kong Government**”) of the Hong Kong Special Administrative Region of the People’s Republic of China under the Medical Device Administrative Control System (“**MDACS**”). MDACS is a listing system for medical devices, under which manufacturers and importers of medical devices could voluntarily list their medical devices with the Department of Health after demonstrating that the relevant medical devices conform to accepted standards of safety and performance.

According to statistics released by the Hong Kong Cancer Registry, colorectal cancer was the second leading cause of cancer-related deaths in Hong Kong in 2022. Consequently, the Hong Kong Government launched the Colorectal Cancer Screening Program to subsidize asymptomatic Hong Kong residents aged 50 to 75 for screening services in the private sector to prevent colorectal cancer. Due to the increasing public awareness of early cancer screening in Hong Kong with the support from the Hong Kong Government, the Company believes there will be a growing potential for early cancer screening market in Hong Kong.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended pending fulfilment of the Resumption Guidance (as defined in the announcement of the Company dated May 28, 2024).

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**New Horizon Health Limited**  
**Mr. YeQing ZHU**  
*Chairman*

Hong Kong, November 19, 2024

*As at the date of this announcement, the Board comprises Mr. YeQing ZHU as Chairman and executive Director, Dr. Yiyou CHEN as executive Director, Mr. Naxin YAO as non-executive Director, and Mr. Danke YU, Dr. Donald Kwok Tung LI, Mr. LAU Ngai Kee Ricky, Ms. NG Weng Sin and Ms. Jiangnan KONG as independent non-executive Directors.*